title: Using NF-κB as a molecular target for theranostics in radiation oncology research.
abstract: Resistance of cancer cells to chemotherapy and/or radiotherapy is a major challenge to current anticancer treatment. The NF-κB signaling pathway plays an important role in tumor development and progression, and results in unsatisfactory treatment outcome. Inhibition of the NF-κB signaling cascade may sensitize the resistant cancer cells to chemotherapy and/or radiotherapy. Here, the correlation of NF-κB molecules with carcinogenesis and tumor progression, along with its significance in clinical practice, is reviewed. The potential clinical application of NF-κB and its associated molecules as diagnostic and therapeutic targets is also discussed.
authors.affiliation: Department of Biomedical Imaging & Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.
authors.forename: Yu-Chang
authors.initials: YC
authors.lastname: Liu
authors.forename: I-Tsang
authors.initials: IT
authors.lastname: Chiang
authors.forename: Fei-Ting
authors.initials: FT
authors.lastname: Hsu
authors.forename: Jeng-Jong
authors.initials: JJ
authors.lastname: Hwang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D006801:Humans; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D018787:Radiation Oncology; D011836:Radiation Tolerance / Q000187:drug effects; D015398:Signal Transduction; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D016328:NF-kappa B; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib